Trials / Recruiting
RecruitingNCT07115043
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Detailed description
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants with Select Advanced or Metastatic Solid Tumors
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma (Skin)
- Renal Cell Carcinoma
- Merkel Cell Carcinoma
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Gastric Cancer/Gastroesophageal Junction Cancer
- High Grade Serous Ovarian Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6750 | AZD6750- CD8 guided IL-2 |
| DRUG | rilvegostomig | Rilvegostomig- PD1-TIGIT bispecific antibody |
Timeline
- Start date
- 2025-07-29
- Primary completion
- 2029-10-02
- Completion
- 2029-10-02
- First posted
- 2025-08-11
- Last updated
- 2026-03-17
Locations
11 sites across 4 countries: United States, Australia, Japan, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07115043. Inclusion in this directory is not an endorsement.